Assessing therapeutic safety and efficacy of Pazopanib, Pembrolizumab plus Axitinib and Nivolumab plus Ipilimumab in Renal Cell Carcinoma: a systematic review and meta-analysis
This thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2023.
| Autor principal: | |
|---|---|
| Outros Autores: | |
| Formato: | Thesis |
| Idioma: | English |
| Publicado em: |
Brac University
2024
|
| Assuntos: | |
| Acesso em linha: | http://hdl.handle.net/10361/23931 |
| id |
10361-23931 |
|---|---|
| record_format |
dspace |
| spelling |
10361-239312024-09-03T10:12:48Z Assessing therapeutic safety and efficacy of Pazopanib, Pembrolizumab plus Axitinib and Nivolumab plus Ipilimumab in Renal Cell Carcinoma: a systematic review and meta-analysis Shawn, Ibna Hasan Jamiruddin, Mohd. Raeed School of Pharmacy, Brac University RCC Demographic analysis Pazopanib Nivolumab plus Ipilimumab Progression-free survival Serious adverse events Overall adverse events Kidneys--Cancer--Molecular aspects. Renal cell carcinoma. This thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2023. Cataloged from the PDF version of thesis. Includes bibliographical references (pages 30-31). Renal cell carcinoma (RCC) is the predominant form of kidney cancer. It is a highly prevalent form of solid tumor, and the limited availability of accurate disease models has impeded progress in the field of human kidney cancer research and treatment. Recent pharmaceutical advances, such as immune checkpoint inhibitors and targeted treatments, have shown promising results for metastatic RCC. Collaborative clinical trials will play a vital role in effectively incorporating these regimens into clinical practice. This systematic review and meta-analysis aim to assessing the efficacy and safety of nivolumab-ipilimumab, pembrolizumab-axitinib and pazopanib in treatment of renal cell carcinoma. The clinical outcome indicators that will be evaluated include overall survival, progression-free survival, hazard ratio, overall adverse events, and severe adverse events. The objective of this research is to identify therapeutic interventions that have the potential to improve the long-term management of renal cell carcinoma (RCC) on a worldwide scale. Ibna Hasan Shawn B. Pharmacy 2024-08-28T08:37:21Z 2024-08-28T08:37:21Z ©2023 2023-11 Thesis ID 18346086 http://hdl.handle.net/10361/23931 en Brac University theses are protected by copyright. They may be viewed from this source for any purpose, but reproduction or distribution in any format is prohibited without written permission. 45 pages application/pdf Brac University |
| institution |
Brac University |
| collection |
Institutional Repository |
| language |
English |
| topic |
RCC Demographic analysis Pazopanib Nivolumab plus Ipilimumab Progression-free survival Serious adverse events Overall adverse events Kidneys--Cancer--Molecular aspects. Renal cell carcinoma. |
| spellingShingle |
RCC Demographic analysis Pazopanib Nivolumab plus Ipilimumab Progression-free survival Serious adverse events Overall adverse events Kidneys--Cancer--Molecular aspects. Renal cell carcinoma. Shawn, Ibna Hasan Assessing therapeutic safety and efficacy of Pazopanib, Pembrolizumab plus Axitinib and Nivolumab plus Ipilimumab in Renal Cell Carcinoma: a systematic review and meta-analysis |
| description |
This thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2023. |
| author2 |
Jamiruddin, Mohd. Raeed |
| author_facet |
Jamiruddin, Mohd. Raeed Shawn, Ibna Hasan |
| format |
Thesis |
| author |
Shawn, Ibna Hasan |
| author_sort |
Shawn, Ibna Hasan |
| title |
Assessing therapeutic safety and efficacy of Pazopanib, Pembrolizumab plus Axitinib and Nivolumab plus Ipilimumab in Renal Cell Carcinoma: a systematic review and meta-analysis |
| title_short |
Assessing therapeutic safety and efficacy of Pazopanib, Pembrolizumab plus Axitinib and Nivolumab plus Ipilimumab in Renal Cell Carcinoma: a systematic review and meta-analysis |
| title_full |
Assessing therapeutic safety and efficacy of Pazopanib, Pembrolizumab plus Axitinib and Nivolumab plus Ipilimumab in Renal Cell Carcinoma: a systematic review and meta-analysis |
| title_fullStr |
Assessing therapeutic safety and efficacy of Pazopanib, Pembrolizumab plus Axitinib and Nivolumab plus Ipilimumab in Renal Cell Carcinoma: a systematic review and meta-analysis |
| title_full_unstemmed |
Assessing therapeutic safety and efficacy of Pazopanib, Pembrolizumab plus Axitinib and Nivolumab plus Ipilimumab in Renal Cell Carcinoma: a systematic review and meta-analysis |
| title_sort |
assessing therapeutic safety and efficacy of pazopanib, pembrolizumab plus axitinib and nivolumab plus ipilimumab in renal cell carcinoma: a systematic review and meta-analysis |
| publisher |
Brac University |
| publishDate |
2024 |
| url |
http://hdl.handle.net/10361/23931 |
| work_keys_str_mv |
AT shawnibnahasan assessingtherapeuticsafetyandefficacyofpazopanibpembrolizumabplusaxitinibandnivolumabplusipilimumabinrenalcellcarcinomaasystematicreviewandmetaanalysis |
| _version_ |
1814309820436578304 |